Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...

In a plenary session at the annual American Academy of Neurology meeting, Paul Edison, MD, PhD, of Imperial College London in ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

They matched 33,220 patients taking semaglutide, liraglutide (Saxenda), exenatide (Byetta, Bydureon), dulaglutide (Trulicity), tirzepatide (Zepbound), and lixisenatide (no longer available in the ...

Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted ...

Among women who have had gestational diabetes, those who sleep 6 hours or less per night or snore may be more likely to develop type 2 diabetes, according to findings reported in JAMA Network Open ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...

Dr. Troy Mensen is a family medicine doctor based in the Chicago area. He completed his undergraduate degree at the University of Northern Iowa and his doctorate at Des Moines University College ...

Expert Rev Endocrinol Metab. 2013;8(3):247-259. It is unclear to what degree these specific changes in CV parameters and risk factors play in overall clinical outcomes. As earlier outlined, short ...